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FABP4 inhibitionFatty acid-binding protein 4 (FABP4) is an adipose tissue-secreted adipokine that is involved in the regulation of
energetic metabolism and inﬂammation. Increased levels of circulating FABP4 have been detected in individuals
with cardiovascular risk factors. Recent studies have demonstrated that FABP4 has a direct effect on peripheral
tissues, speciﬁcally promoting vascular dysfunction; however, itsmechanism of action is unknown. The objective
of this work was to assess the speciﬁc interactions between exogenous FABP4 and the plasma membranes of
endothelial cells. Immunoﬂuorescence assays showed that exogenous FABP4 localized along the plasma
membranes of human umbilical vein endothelial cells (HUVECs), interacting speciﬁcally with plasmamembrane
proteins. Anti-FABP4 immunoblotting revealed two covalent protein complexes containing FABP4 and its
putative receptor; these complexes were approximately 108 kDa and 77 kDa in size. Proteomics and mass
spectrometry experiments revealed that cytokeratin 1 (CK1)was the FABP4-binding protein. An anti-CK1 immu-
noblot conﬁrmed the presence of CK1. FABP4-CK1 complexes were also detected in HAECs, HCASMCs, HepG2
cells and THP-1 cells. Pharmacological FABP4 inhibition by BMS309403 results in a slight decrease in the
formation of these complexes, indicating that fatty acids may play a role in FABP4 functionality. In addition,
we demonstrated that exogenous FABP4 crosses the plasma membrane to enter the cytoplasm and
nucleus in HUVECs. These ﬁndings indicate that exogenous FABP4 interacts with plasma membrane proteins,
speciﬁcally CK1. These data contribute to our current knowledge regarding themechanismof action of circulating
FABP4.
© 2015 Published by Elsevier B.V.1. Introduction
Fatty acid-binding protein 4 (FABP4; adipocyte-FABP; aP2) is a
member of the family of intracellular fatty acid-binding proteins
(FABPs), which are ~15 kDa in weight and 126–134 amino acids in
length [1,2]. FABPs are expressed abundantly (1–5% of cytosolic pro-
teins) in cells involved in active lipid metabolism. Members of the
FABP family exhibit unique tissue-speciﬁc expression patterns and are
named according to the tissues in which they were ﬁrst identiﬁed [3].
FABPs are capable of binding a variety of hydrophobic ligands, such as
long-chain fatty acids, eicosanoids, leukotrienes and prostaglandins
[4–6]. However, the divergent sequences of the members confer subtle-binding protein 4; FABP4-His,
P, fatty acid-binding proteins;
sis Research Unit, Facultat de
43201 Reus (Tarragona), Spain.differences in their ligand-binding properties andmay also indicate dif-
ferent protein–protein interaction partners depending on the cellular
context. Indeed, it has been shown that intracellular adipocyte-,
epithelial-, and heart-type FABPs interact with hormone-sensitive li-
pase, whereas the intestinal and liver isoforms do not [3–7]. It is also
known that FABP4 interacts with Janus Kinase 2 in a fatty acid-
dependent manner, establishing a new role for FABP4 as a fatty acid
sensor that affects cellular metabolism via protein–protein interactions
[8]. FABP4 is highly expressed in adipocytes andmacrophages and has a
role in lipidmetabolism in both cell types [8]. FABP4 expression has also
been reported in endothelial cells [9]. The biological relevance of FABP4
is underscored by the ﬁndings that FABP4 knockout (FABP4 −/−) mice
exhibit marked protection against insulin resistance, atherosclerosis,
fatty liver disease, and asthma [5,10–14]. Consistent with these studies,
a small-molecule inhibitor of FABP4 (BMS309403) has been found to be
an effective therapeutic agent for the treatment of atherosclerosis and
type 2 diabetes mellitus (T2DM) inmousemodels [15]. FABP4 is secret-
ed from adipocytes via a non-classical, calcium-dependent mechanism
[16] that is regulated by lipolytic pathways [17]. It has been demonstrat-
ed that adipocyte lipases, speciﬁcally adipose triglyceride lipase (and, to
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secretion of FABP4 [18]. In the last several years, much effort has been
focused on determining the role of circulating FABP4.We and other au-
thors have shown that FABP4 levels are increased in obesity, metabolic
syndrome, T2DM, and familial combined hyperlipidemia and
lipodystrophy syndromes. In addition, FABP4 levels are closely correlat-
ed with adverse lipid proﬁles and insulin resistance [19–25]. FABP4
serum levels independently predict the risks of developing metabolic
syndrome, T2DM and atherosclerotic disease [24,26–28]. A recent
study has found that circulating FABP4 levels are inversely associated
with peripheral reactive hyperemia, a surrogate marker of endothelial
dysfunction [29]. In addition, it has been demonstrated that increased
levels of FABP4 in atherosclerotic lesions are associated with unstable
plaque phenotypes [30,31]. Extracellular FABP4 also directly decreases
the contractility of myocardial muscle cells, suggesting that its release
into the bloodstream could directly affect certain peripheral cells and
tissues [32]. Recent results from our group have shown that along
with a decrease in eNOS expression, extracellular FABP4 increases the
expression of vascular cell adhesion protein 1 (VCAM1), E-selectin
and leukocyte adhesion to endothelial cells; these results suggest that
FABP4 has a global effect on endothelial function [33]. Furthermore,
FABP4 directly affects the migration and proliferation of human artery
coronary smooth muscle cells (HCASMCs). This result suggests a role
for FABP4 in vascular remodeling that is mediated primarily through a
MAPK-dependent pathway, which activates the transcription factors
c-jun and c-myc in HCASMCs [34].
These data prompted us to investigate the interactions of exogenous
FABP4with plasmamembrane proteins in endothelial cells. Here, based
on the results of immunoﬂuorescence and cross-linking immunoblot
experiments, we report the cell-surface localization of exogenous
FABP4 protein complexes. Proteomics analysis subsequently revealed
that FABP4 binds speciﬁcally with cytokeratin 1 (CK1).2. Materials and methods
2.1. Cell culture, treatment and protein extracts
Human umbilical vein endothelial cells (HUVECs) (passage 3) and
human aortic endothelial cells (HAECs) were cultured in Medium 200
supplemented with 2% low serum growth supplement (LSGS) and 1%
gentamicin/amphotericin (GIBCO®, Oregon, OR, USA). Human coronary
aortic smooth muscle cells (HCASMCs) were cultured in Medium 231
supplemented with 2% smooth muscle growth supplement (SMGS) and
1%gentamicin/amphotericin (GIBCO®).Monocyte-derivedTHP-1macro-
phages (DSMZ, Braunschweig, Germany) were cultured in RPMI supple-
mented with 10% fetal bovine serum (FBS), 1% penicillin/streptomycin
and 1% L-glutamine (BioWest, Kansas City, MO, USA). HepG2 cells
(ATTC, Manassas, VA, USA) were cultured in MEMmedium supplement-
ed with 10% FBS, 1% penicillin/streptomycin, 1% L-glutamine and 1% non-
essential amino acids (NEAA) (BioWest).
The cells were incubated with or without human recombinant FABP4
(100 ng/mL) (BioVendor, Heidelberg, Germany) or human recombinant
polyhistidine-tag FABP4 (FABP4-His) (Enzo Life Sciences, San Diego, CA,
USA) for the indicated times. In some experiments, HUVECs were
incubated with the FABP4 inhibitor BMS309403 {2-[2′-(5-ethyl-3,4-
diphenyl-1H-pyrazol-1-yl)biphenyl-3-yloxy] acetic acid} at 10 μM
(Calbiochem, San Diego, CA, USA). Dimethyl sulfoxide (DMSO) was
used as a solvent control (Sigma-Aldrich).
Cell plasmamembrane lysates were obtained as previously reported
[35]. Brieﬂy, the cells were incubatedwith cold buffer (50mMTris–HCl,
pH 7.4, 150mMNaCl, 2mMCa2+, 1% Triton X-100, 1% NP40, and prote-
ase inhibitor cocktail (Roche, Indianapolis, IN, USA) and kept on ice for
15 min. After incubation, the lysates were centrifuged at 16,000 × g
for 15 min, and the supernatant was collected. Nuclear and cytoplasmic
protein extracts were obtained as previously described [34].2.2. Immunoblotting
Protein concentrations were determined using the Bradford assay
(Bio-Rad, Hercules, CA, USA). Electrophoresis and immunoblot analyses
were performed using the NuPAGE protein analysis system (Invitrogen
Life Technologies, Carlsbad, CA, USA). The membranes were incubated
with anti-FABP4 (R&D Systems, Minneapolis, MN, USA), anti-His-tag
(Abcam, Cambridge, MA, USA), anti-actin (Santa Cruz Biotechnology,
Santa Cruz, CA, USA), anti-CD31 (DAKO, Glostrup, Denmark) and anti-
cytokeratin 1 (CBL266) (MerckMillipore, Billerica,MA, USA) antibodies.
The antigen-antibody complexes were detected by incubating the
membrane with HRP-conjugated anti-IgG antibodies (DAKO). The
bands were visualized using a ChemiDoc Image System and quantiﬁed
with Image Lab analysis software (Bio-Rad). The relative levels of
FABP4 were quantiﬁed after normalization with CD31 or actin levels.
All of the values were expressed in arbitrary units (AU). The molecular
weights of the bands were assigned by comparing the band weights
with BenchMark™ Protein Ladder (Invitrogen Life Technologies) using
ImageQuant TL v7.0 v (GE Healthcare, Wauwatosa, WI, USA).
2.3. Immunoﬂuorescence microscopy
For the colocalization experiments, HUVECs were incubated in
chambered slides (Nunc, Roskilde, Denmark) with or without FABP4,
ﬁxed with 4% paraformaldehyde (Sigma-Aldrich) for 20 min at 4 °C
and washed at each step three times with DPBS (GIBCO®) for 5 min.
The cells were then incubated overnight at 4 °C with anti-FABP4 and
anti-CD31 antibodies and further incubated with Alexa Fluor® 488
anti-goat and Alexa Fluor® 532 anti-mouse antibodies (Invitrogen Life
Technologies) for 3 h at RT. The antibodies were diluted in the blocking
solution (DPBS, 2% FBS, and 0.1% BSA). Confocal immunoﬂuorescence
images were captured with a Nikon Eclipse TE2000-E microscope and
processed with EZ-C1 3.40 software (Nikon, Chiyoda, Tokyo, Japan).
For the internalization experiments, the cells were permeabilized
after ﬁxation with a solution containing DPBS, 2% FBS, 0.1% BSA, and
0.1% Triton X-100 for 5 min at RT. The cells were then incubated with
blocking solution for 20 min at RT. The cells were incubated overnight
at 4 °C with an anti-FABP4 antibody and further incubated with an
Alexa Fluor® 488 anti-goat antibody for 3 h at RT. The cells were then
incubated with the nuclear stain DAPI (4′,6-diamidino-2-phenylindole,
dilactate) and CellMask™ Deep Red Plasma Membrane Stain
(Invitrogen Life Technologies) for 5 min. Immunoﬂuorescence images
were captured with an Olympus IX71 inverted microscope, processed
with Cell^F Software (Olympus, Shinjuku-ku, Tokyo, Japan) and quanti-
ﬁed with ImageJ (Fiji, Madison, WI, USA).
2.4. HUVEC crosslinking
After incubation with or without FABP4-His, the HUVECs were
cross-linked with 2% formaldehyde in DPBS at RT for 30 min, as previ-
ously reported [36,37]. The cells were washed once in DPBS, and
HUVEC plasma membrane protein extraction was performed as men-
tioned above.
2.5. Polyhistidine-tagged protein puriﬁcation
Plasma membrane proteins from HUVECs that were incubated with
or without FABP4-His were puriﬁed according to the instructions pro-
vided with the HisPur™ Cobalt Puriﬁcation Kit, which was purchased
from Pierce (Rockford, IL, USA).
2.6. Ligand screening assay
Plasmamembrane proteins fromHUVECs incubatedwith orwithout
FABP4-His were analyzed with the FABP4 Inhibitor/Ligand Screening
Assay Kit (Cayman Chemical Company, Ann Harbor, MI, USA) to detect
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rescent probe that ﬂuoresces when bound to FABP4 and recombinant
FABP4 (10 mM). Any FABP4 ligand can displace the ﬂuorescent probe,
thereby reducing ﬂuorescence. We used arachidonic acid (1.28 mM), a
known ligand of FABP4, as a positive control. The binding of the ﬂuores-
cent probe to FABP4wasmonitored bymeasuring excitation at 370mm
and emission at 475 mm using a Synergy HT ﬂuorometer (BioTek,
Winooski, VT, USA). The obtained results were presented as the percent
ﬂuorescence of each sample (plasma membrane proteins) relative to
the ﬂuorescence maximum (FABP4 + ﬂuorescence probe).
2.7. Small interfering RNA (siRNA) transfection
To knock down FABP4 expression, ON-TARGETplus siRNAs targeting
human FABP4 (J-008,853–08–0005) andGAPDH (D-001,830–01–05) as
a control were purchased from Dharmacon (Lafayette, CO, USA). The
cells were transiently transfected using Lipofectamine® RNAiMax
(Invitrogen Life Technologies) and analyzed after 72 h.
2.8. Quantitative real-time PCR
Total RNA was isolated from the cells using the ABI PRISM 6100
Nucleic Acid PrepStation kit (Applied Biosystems, Carlsbad, CA, USA).
The absorbance at 260 nm was used to determine the RNA concentra-
tion, and the 260/280 ratio was used to determine the RNA quality.
Total RNA (0.5 μg) was reverse transcribed to cDNA using random
hexamers and SuperScript II (Invitrogen Life Technologies), following
the manufacturer's protocol. Pre-designed and validated TaqMan Gene
Expression Assay (Life Technologies) primers and probeswere obtained
for FABP4 (Hs00609791_m1) and 18S (Hs99999901_s1) and used for
real-time PCR ampliﬁcation. The mRNA expression of each gene and
sample was calculated using the recommended 2-ΔΔCt method.
Untreated cells were considered as controls in this experiment. 18S
was used as a housekeeping gene to normalize the results for the gene
of interest.
2.9. Proteomics sample preparation and MS analysis
Concentrated HUVEC plasma membrane proteins were incubated
with or without FABP4-His, and impurities were removed using a 2D
clean-up kit (GE Healthcare) according to the manufacturer's instruc-
tions. After quantiﬁcation, the samples were separately labeled with ei-
ther Cy3 or Cy5 according to the manufacturer's protocol. The labeled
samples were mixed and combined for MS analysis.
First-dimension separation was performed with an IPGphor isoelec-
tric focusing (IEF) unit (GE Healthcare), in which the sampleswere load-
ed onto 7-cm, pH 3–10 immobilized pH gradient (IPG) strips with
passive rehydration for 16 h. This step was followed by isoelectric focus-
ing for a total of 7000 V/h. The strips were immediately equilibrated in
SDS equilibration buffer (6 M urea, 30% glycerol, 2% SDS, 75 mM Tris Cl,
pH 8.8, and 0.005% bromophenol blue) for 15 min with 1% (w/v) DTT.
The strips were then equilibrated for 15 min with SDS buffer with 2.5%
(w/v) iodoacetamide (IAA). For the second dimension of separation,
the strips were applied directly to a 12% SDS-polyacrylamide gel.
Immediately after 2D-DIGE was performed, the gels were scanned with
a Pharos FX™ Plus Molecular Imager scanner using excitation/emission
ﬁlters of 532/580 nm for Cy3 and 633/670 nm for Cy5 to generate
multiplexed DIGE image ﬁles. Statistical and quantitative analyses of
the changes in the spots on the imageswere performed using Progenesis
SameSpots software v4.1 (Nonlinear Dynamics). Spots that were only
present in the FABP4-His-incubated cells were selected for further iden-
tiﬁcation. Lastly, the gel was stained with a PlusOne Silver Staining Kit
(GE Healthcare), following the manufacturer's recommendations.
Protein spots were selected and digested with trypsin [38]. Brieﬂy,
the gel pieces were de-stained by three washes in 25 mM NH4HCO3,
with vortexing, for 15min and one wash in 100% CH3CN. The gel pieceswere dried and then swelled by incubation with digestion buffer
(50 mM NH4HCO3 and 12.5 ng/mL of autolysis-stabilized trypsin)
(Promega, Madison, WI, USA) at 37 °C for 16 h. The peptides were ex-
tracted sequentially in 0.1% triﬂuoroacetic acid (TFA) and 0.1% TFA in
50% CH3CN and vacuum-dried. Lastly, the peptides were washed using
Zip-tip C18 columns (Millipore), and the elutions were recovered with
a 50% CH3CN and 0.1% TFA solution.
The peptides were spotted onto an AnchorChip (Bruker, Bremen,
Germany) target using α-cyano-4-hydroxy-cinnamic acid as a matrix.
The peptideswere then analyzedwith aMALDI TOF/TOF (Ultraﬂextreme,
Bruker Daltonics) instrument operated in the positive ion mode. The an-
alyzed mass range was 700–3500 Da, with ion suppression of up to
600 Da. MS and MS/MS analyses were performed automatically. For the
MS analysis, 1500 single-shot spectra were accumulated by recording
50-shot spectra at 10 random positions using ﬁxed laser attenuation.
The selection of precursor ions for MS/MS was performed using an
Autoexecuteworkﬂowwith FlexControl software v3.4 (BrukerDaltonics).
For theMS/MS analysis, 100 single-shot spectrawere recorded for precur-
sors, and 3000 single-shot spectra were recorded for the fragment ion
spectra. The peptide and tandem mass spectra were searched using
MASCOT (Matrix Science Inc., MA) against the Swiss-Prot database
(released on 03/2013), focusing on human taxonomy. The search pa-
rameters were as follows: MS accuracy = 75 ppm, MS/MS accuracy =
0.7 Da, two missed cleavages by trypsin allowed, carbamidomethyl of
cysteine as a ﬁxed modiﬁcation and oxidation of methionine as a vari-
able modiﬁcation.
2.10. GeLC-MS/MS analysis
The concentrations of plasmamembrane proteins fromHUVECs that
were incubatedwith orwithout FABP4-Hisweremeasured by the Brad-
ford assay, using BSA as a standard. SDS-PAGE analysis was carried out
with 5 μg of these samples, which were run on a 12% acrylamide mini-
gel. After completion of the run, the gel was visualized by colloidal
Coomassie Blue stain (Invitrogen Life Technologies). Following visuali-
zation of the gels, each lane was completely cut out in ten pieces using
a scalpel and placed into a 0.5-mL Eppendorf tube for in-gel digestion.
The protein bands were excised from the gel and shrunk by dehy-
dration in acetonitrile, which was then removed. The resulting spots
were dried in a vacuum centrifuge. The gel pieces were covered with
10 mM dithiothreitol (DTT), and the proteins were reduced for 1 h at
56 °C. After cooling to RT, the DTT solution was replaced with approxi-
mately the same volume of 55 mM iodoacetamide in 100 mM
NH4HCO3. After 45 min of incubation at an ambient temperature in
the dark with occasional vortexing, the gel pieces were washed with
100 mM NH4HCO3 for 10 min, dehydrated by the addition of acetoni-
trile, swelled by rehydration in 100 mM NH4HCO3, and shrunk again
by addition of the same volume of acetonitrile. The liquid phase was re-
moved, and the gel pieces were completely dried in a vacuum centri-
fuge. The gel pieces were swollen in a digestion buffer containing
50 mM NH4HCO3 and 12.5 ng/mL of autolysis-stabilized trypsin
(Promega) in an ice-cold bath. After 45 min, the supernatant was re-
moved and replaced with the same buffer without trypsin to keep the
gel pieces wet during enzymatic cleavage (37 °C, overnight). The pep-
tides were extracted by one change of 20 mM NH4HCO3 and three
changes of 5% formic acid in 50% acetonitrile (20 min for each change)
at RT and dried.
Analysis was performedwith an Esquire HCT ion trapmass spectrom-
eter (Bruker) coupled to a nano-HPLC system (Proxeon, Denmark). The
samples were ﬁrst concentrated on a 300-μm i.d. 1-mm PepMap
nanotrapping column and then loaded onto a 75-μm i.d. 15-cm PepMap
nanoseparation column (LC Packings, The Netherlands). The peptides
were eluted with an acetonitrile gradient (gradient: 0–60% B in
60 min; B = 80% acetonitrile and 0.1% formic acid in water; ﬂow
rate = 300 nL/min) through a PicoTip emitter nano-spray needle
(New Objective, Woburn, MA, USA) onto the nanospray ionization
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m/z 100–2800) was performed for two of the most intense ions, as de-
termined from a 1.2-sMS survey scan (m/z 310–1500), using a dynamic
exclusion time of 1.2min for precursor selection. An automated optimi-
zation of the MS/MS fragmentation amplitude starting from 0.60 V was
used. The proteins were identiﬁed by searching the UniProt-SwissProt
57.9 human database using Mascot (Matrix Science, London, UK). The
MS/MS spectra were searched with a precursor mass tolerance of
1.5 Da, fragment tolerance of 0.5Da, trypsin speciﬁcitywith amaximum
of two missed cleavages allowed, carbamidomethylation as a ﬁxed
modiﬁcation, and methionine oxidation as a variable modiﬁcation.
The positive identiﬁcation criterion was an individual Mascot score for
each peptide MS/MS spectrum that was higher than the corresponding
homology threshold score.2.11. Statistical analysis
The results are the average of 3 independent experiments, which
were each performed in duplicate (presented as the mean ± SEM).
GraphPad Prism was used for statistical analysis (version 5, San Diego,
CA, USA), and Student's t-test was used to compare the means. Differ-
ences between the two groups were considered statistically signiﬁcant
at p b 0.05.Fig. 1. The presence of exogenous FABP4 in the plasmamembranes of HUVECs. (A) FABP4 and C
with or without exogenous FABP4 (100 ng/mL) for different times (0–4 h). The bar graph repr
images from double immunoﬂuorescence staining for CD31 (Alexa Fluor® 532 dye) and FABP4
cubatedwith orwithout exogenous FABP4 for 5min. (C)Double immunoﬂuorescence staining f
membrane permeabilization in both non-transfected and FABP4-siRNA-transfected HUVECs tha
was performed after normalization for CD31 levels. The results are presented as the mean ± S3. Results
3.1. Exogenous FABP4 is found in plasma membranes of HUVECs
We incubated HUVECs with or without FABP4-His for 5 min,
15 min, 30 min, 1 h, 2 h and 4 h, and the plasma membrane protein
extracts were analyzed. An anti-FABP4 immunoblot revealed a 2.2-
fold increase in FABP4 levels when the cells were incubated with
FABP4-His for 5 min compared with the cells incubated without
FABP4-His (p b 0.05). When cells were incubated without exogenous
FABP4, the levels remained constant throughout the 4 h of the experi-
ment (Fig. 1A).
HUVECs were incubated with or without exogenous FABP4 for
5 min, and double-immunoﬂuorescence staining with anti-FABP4 and
anti-CD31 (a HUVEC plasma membrane protein marker) without per-
meabilization was performed. Confocal images revealed colocalization
of FABP4 and CD31 (Fig. 1B). Immunoﬂuorescence images showed an
increased presence of FABP4 in cells that were incubated with exoge-
nous FABP4 compared to those that were not (1.3-fold increase,
p b 0.05) (Fig. 1C).
After knocking down FABP4 expressionwith siRNA, we repeated the
immunoﬂuorescence experiments without permeabilization and ob-
served an increase in the amount of FABP4 in HUVECs incubated with
exogenous FABP4 (2.3-fold increase, p b 0.05) (Fig. 1C).D31western blots of plasmamembrane protein lysates fromHUVECs that were incubated
esents the quantitation of FABP4 expression levels in the plasma membrane. (B) Confocal
(Alexa Fluor® 488 dye), without plasma membrane permeabilization. The cells were in-
or CD31 (Alexa Fluor®532 dye) and FABP4 (Alexa Fluor®488dye)wasperformedwithout
t were incubatedwith orwithout exogenous FABP4 for 5min. The quantiﬁcation of FABP4
EM and represent the average of 3 independent experiments (*p b 0.05).
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proteins
We performed a ligand-screening assay using plasma membrane
proteins from HUVECs to determine whether the proteins present in
the extracts were bound to FABP4. We analyzed increasing protein
concentrations (from 0 to 60,000 pg/mL) of plasmamembrane proteins
fromHUVECs incubatedwith orwithout exogenous FABP4 (100 ng/mL)
for 5min.We observed that when cells were incubatedwith exogenous
FABP4, the amount of FABP4 protein detected by ﬂuorescence increased
in a concentration-dependent manner (Fig. 2A). This increase was
presumably due to the presence of exogenous FABP4 in the plasma
membrane. However, when cells were incubated without exogenous
FABP4, we observed a concentration-dependent reduction in ﬂuores-
cence, indicating the presence of FABP4 ligands in the plasma mem-
branes of the HUVECs (Fig. 2A).
Next, HUVECs were incubated with or without FABP4-His
(100 ng/mL) for 5 min, followed by formaldehyde cross-linking,
plasma membrane protein extraction, poly-His-Tag puriﬁcation and
western blotting. An anti-FABP4 western blot showed no bands
for the cells incubated without FABP4-His, and 4 different bands
(approximately 16, 33, 77 and 108 kDa) were detected for the cells in-
cubated with FABP4-His (Fig. 2B and Supp. Fig. 1S). An anti-6X His-tag
western blot also showed the 4-band proﬁle (Fig. 2C). HUVECs that
were incubated with high levels of tag-free FABP4 (100 ng/mL) andFig. 2. Speciﬁc interactions between exogenous FABP4 and plasmamembrane proteins fromHU
or without FABP4-His (100 ng/mL); arachidonic acid (1.28 mM) was included as a positive con
with or without FABP4-His and after poly-His-tag puriﬁcation (eluted and wash fractions), us
recombinant protein and plasma membrane protein lysates from HUVECs after incubation w
FABP4 and the 6X His-tag. (D) Western blot of plasma membrane proteins incubated in coba
His-tag antibodies. (E) FABP4 expression after transfecting HUVECs with siRNA FABP4 as dete
of plasma membrane protein lysates from non-transfected and FABP4- and GAPDH-siRNA-tra
His-tag puriﬁcation. The results are presented as the mean ± SEM and represent the average olow levels of FABP4-His (10 ng/mL) showed only 16- and 33-kDa
bands (the 33-kDa band was a FABP4 homodimer [39]), indicating
that the bands at 77 and 108 kDa represented speciﬁc complexes
formed by exogenous FABP4 and its putative receptor (Fig. 2B and
Suppl. Fig. 1S).
We incubated HUVEC plasmamembrane proteins in the presence or
absence of FABP4-His inside cobalt columns to conﬁrm complex
formation. Anti-FABP4 and anti-6X His-tag immunoblots showed 16-,
33-, 77- and 108-kDa bands, conﬁrming the existence of these com-
plexes (Fig. 2D).
We next knocked down FABP4 expression in HUVECs (Figs. 1C, 2E)
and incubated the cells with or without FABP4-His (100 ng/mL) for
5 min, followed by formaldehyde cross-linking, plasmamembrane pro-
tein extraction, poly-His-tag puriﬁcation and western blotting. An anti-
FABP4 western blot (Fig. 2F) showed 4 different bands (approximately
15, 33, 77 and 108 kDa) in the FABP4-deﬁcient cells incubated with
FABP4.
HUVECs were incubated with or without FABP4-His (100 ng/mL)
for 5 min, 10 min or 15 min, followed by formaldehyde cross-linking,
plasma membrane protein extraction, poly-His-Tag puriﬁcation and
western blotting to determine whether the interaction between
FABP4 and its putative receptor was stable or transient. We observed
that the complex formation peaked at 5 min (Fig. 3A); the amount of
the complex observed at the plasma membrane began to decrease
after 5 min.VECs. (A) Displacement curves of plasmamembrane proteins fromHUVECs incubatedwith
trol. (B) Western blot of plasma membrane protein lysates from HUVECs after incubation
ing antibodies against FABP4. (C) Western blot of FABP4-His recombinant protein, FABP4
ith or without FABP4-His and after poly-His-tag puriﬁcation, using antibodies against
lt resin columns with or without FABP4-His and visualized with anti-FABP4 and anti-6X
rmined by western blot analysis and quantitative real-time PCR. (F) FABP4 western blot
nsfected HUVECs that were incubated with or without FABP4-His and subjected to poly-
f 3 independent experiments (*p b 0.05).
Fig. 3. Exogenous FABP4 is internalized by HUVECs. (A) FABP4 western blot of plasma membrane protein lysates from HUVECs after incubation with or without FABP4 (100 ng/mL) for
different times (0–15 min) and poly-His-tag puriﬁcation. (B)Western blot, using antibodies against FABP4, of cytoplasmic and nuclear protein lysates from HUVECs that were incubated
with or without FABP4-His (100 ng/mL) for different times (0–2 h) and subjected to poly-His tag puriﬁcation. (C) Triple immunoﬂuorescence staining of the nucleus (DAPI), membrane
(CellMask) and FABP4 (Alexa Fluor® 488 dye)was performed on permeabilized HUVECs that were incubatedwith orwithout exogenous FABP4 for three different periods of time (5min,
30 min or 2 h).
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membrane to enter the cytoplasm and nucleus in HUVECs, we incubat-
ed cells with or without FABP4-His for different times (0min, 30min or
2 h) and extracted the cytoplasmic and nuclear proteins. Following
poly-His-tag puriﬁcation, immunoblot analysis revealed the presence
of FABP4 in the cytoplasm after incubation with exogenous FABP4 for
30min or 2 h and the presence of FABP4 in the nucleus after incubation
with exogenous FABP4 for 2 h (Fig. 3B). After permeabilizing the cells,
triple ﬂuorescence staining with anti-FABP4, CellMask and DAPI was
performed on HUVECs that had been incubated with or without exoge-
nous FABP4 for 5 min, 30 min or 2 h. In cells that were incubated with
exogenous FABP4, the FABP4 immunoﬂuorescence (green) changed
from being associated with the plasma membrane (5 min) to being as-
sociated with the nucleus (2 h), which indicated that FABP4 migrated
from the plasma membrane to the nucleus (Fig. 3C). Conversely, in
cells that were not incubated with exogenous FABP4, the same immu-
noﬂuorescence proﬁle did not appear (Fig. 3C). These data were corrob-
orated by western blot (Fig. 3B).Fig. 4. BMS309403 decreases exogenous FABP4 complex formation. FABP4 western blot of pla
(100 ng/mL), with or without BMS309403 (10 μM), and following poly-His tag puriﬁcation (el3.3. Fatty acids are required for the formation of FABP4 protein complexes
HUVECs were incubated with or without FABP4-His (100 ng/mL) in
the presence or absence of the inhibitor BMS309403 (10 μM) for 5 min.
This incubation was followed by formaldehyde cross-linking, plasma
membrane protein extraction, poly-His-tag puriﬁcation and western
blotting. Fig. 4 indicates weak decreases in the formation of the 108
and 77 kDa complexes, suggesting that the binding of fatty acids to
FABP4 was necessary for these interactions.3.4. Identiﬁcation of cytokeratin 1 as the binding protein
Two-dimensional gel electrophoresis was performed with plasma
membrane extracts from HUVECs that were incubated with or without
FABP4-His followed by formaldehyde cross-linking, plasma membrane
protein extraction and poly-His-tag puriﬁcation (Fig. 5A). The samples
were labeled with different CyDye ﬂuorochromes (Cy5 for proteinssma membrane protein lysates from HUVECs after incubation with or without FABP4-His
uted and wash fractions).
Fig. 5. Identiﬁcation of CK1 as a FABP4 binding protein. (A) Representative overlapping 2D-GEL expression maps of plasmamembrane protein lysates from HUVECs after incubation with
or without FABP4-His (100 ng/mL) and following labeling with ﬂuorescent dyes: Cy3 (green) corresponds to incubation with FABP4, and Cy5 (red) corresponds to incubation without
FABP4. This image is representative of 1 of 3 analyzed gels. (B) CK1 western blot of plasma membrane protein lysates from HUVECs after incubation with or without FABP4-His and
poly-His tag puriﬁcation. (C) Western blot of plasma membrane proteins that were incubated in cobalt resin columns with or without FABP4-His and visualized with antibodies against
CK1.
Fig. 6. Speciﬁc protein interactions of exogenous FABP4 and CK1 in HAECs, HCASMCs,
HepG2 cells and THP-1 cells. FABP4 (A) and CK1 (B) western blots of plasma membrane
protein lysates from HAECs, HCASMCs, HepG2 cells and THP-1 cells after incubation
with or without FABP4-His (100 ng/mL) and following poly-His tag puriﬁcation.
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HUVECs incubated with FABP4-His). A total of 98 spots were detected,
82 of which were detected in the samples incubated both with and
without exogenous FABP4 and 16 that were only present in the sample
incubatedwith exogenous FABP4. These 16 spotswere excised, trypsin-
digested and analyzed by MALDI-TOF/TOF. The mass spectrometry
results showed a compatible binding proﬁle between FABP4 and
cytokeratins, speciﬁcally human CK1 (P04264 (K2C1_HUMAN)). This
identiﬁcation was conﬁrmed by another proteomic strategy, GeLC-MS/
MS analysis, for which protein samples were fractioned by performing
1D-gel electrophoresis prior to nano-LC ESI. Each lane was cut into 10
small pieces, in-gel digestionwas performed, and the peptides were an-
alyzed with a nano-LC ESI q-TOF mass spectrometer. Lastly, deﬁnitive
validation was achieved by western blot using an anti-CK1 antibody
(Fig. 5B). The immunoblot revealed three bands of approximately 108,
77 and 65 kDa. The 108- and 77-kDa complexes were formed by
FABP4 and CK1, while the 65-kDa band represented CK1 released
from the complexes in the western blot.
3.5. Exogenous FABP4 forms protein complexes in HAECs, HCASMCs, HepG2
cells and THP-1 cells
HAECs, HCASMCs, HepG2 cells and THP-1 cells were incubated with
orwithout FABP4-His (100 ng/mL) for 5min, followed by formaldehyde
cross-linking, plasmamembrane protein extraction, poly-His-tag puriﬁ-
cation and western blotting. The anti-FABP4 immunoblot (Fig. 6A)
showed the 4-band proﬁle (15, 33, 77 and 108 kDa) for these cells, indi-
cating that FABP4 formed protein complexes with plasma membrane
proteins. The anti-CK1 immunoblot (Fig. 6B) also indicated that these
protein complexes were formed by FABP4 and CK1.
4. Discussion
Themajor ﬁnding of this study is that exogenous FABP4 is able to in-
teract with plasma membrane proteins, forming speciﬁc protein com-
plexes with CK1 in HUVECs. We demonstrated that exogenous FABP4
is localized in the plasma membrane in speciﬁc protein complexes in
HUVECs and that fatty acids are required to form FABP4 protein
complexes.Previous studies have postulated that FABP4 is a plasmatic biomarker
of metabolic syndrome, T2DM and atherosclerotic disease [24,26–28]. In
this study, interactions between exogenous FABP4 and the plasmamem-
branes ofHUVECswere shown, supporting the hypothesis that circulating
FABP4 is not simply a biomarker but that it may have a causal effect by
interacting with peripheral cells. In addition, we observed that these in-
teractions occurred through speciﬁc protein complexes, even in FABP4-
deﬁcient HUVECs.
We observed that exogenous FABP4 could be internalized into
HUVECs, passing through the cell membrane into the cytoplasm after
30 min and into the nucleus after 2 h. It is known that CK1 is an endo-
thelial receptor that aids in the internalization of myeloperoxidase
[40], so it is possible that CK1 also aids in the internalization of FABP4.
However, it is not known whether this internalization occurs due to
the interaction between FABP4 and CK1 or whether free FABP4
(15 kDa) can pass through the membrane into the cytoplasm; both
2973P. Saavedra et al. / Biochimica et Biophysica Acta 1853 (2015) 2966–2974means of internalization are possible. We do know, however, that
FABP4 and CK1 interact only transiently in the plasma membrane
given that levels of the protein complex decreased after 5 min. In sup-
port of our results, the amount of intracellular FABP4 has been observed
to increase following FABP4 incubation compared with non-treated
cells [33]. It has also been shown that exogenous FABP4 can be taken
up into cells [41].
We observed that administration of a FABP4 inhibitor (BMS309403)
decreased complex formation between exogenous FABP4 and CK1.
Therefore, fatty acids play an important role in FABP4 functionality, de-
creasing its interaction with plasma membrane proteins from HUVECs.
BMS309403 is a biphenyl azole inhibitor designed to target FABP4.
This compound competitively binds within the FABP4 fatty acid-
binding pocket and inhibits the binding of FABP4 to endogenous free
fatty acids [42,43]. Mechanistically, BMS309403 inhibits lipid accumula-
tion, cholesterol efﬂux and inﬂammatory responses in macrophages,
suppresses fatty acid uptake in adipocytes in a FABP4-dependent man-
ner and stimulates glucose uptake through selective activation of the
AMPK signaling pathway [43,44]. It is possible that the protection
against atherosclerosis and T2DM provided by BMS309403 is due in
part to a decrease in FABP4 complex formation.
This study used two proteomics strategies, both of which identiﬁed
CK1 as the FABP4-binding protein in the plasmamembranes of HUVECs.
First, using MALDI TOF/TOF mass spectrometry, we analyzed plasma
membrane protein lysates from HUVECs incubated with or without
FABP4-His after cross-linking and puriﬁcation with cobalt resin. The
MALDI TOF/TOF proﬁles revealed that CK1 was the putative FABP4-
binding protein. We repeated the procedure but used GeLC-MS/MS for
the analysis, which also showed that CK1 was the putative receptor.
CK1 was again conﬁrmed to be the FABP4 receptor by immunoblot.
Cytokeratins are known to be part of a family of intermediate ﬁla-
ment proteins that participate in cytoskeletal assembly [45]. CK1 is a
member of the basic-neutral subfamily of cytokeratins [46]. In endothe-
lial cells, CK1 appears to play a role as an anchor or receptor for various
active molecules [45]. CK1 was also shown to colocalize with uPAR to
form amultiprotein receptor complex for high-molecular-weight kinin-
ogen binding at the cell surface [47,48]. Furthermore, it was demon-
strated that endothelial oxidative stress increases CK1 cell-surface
protein expression and its ability the bind proteins (mannose-binding
lectin) [49]. In addition, CK1 has been determined to be involved in vas-
cular biology by regulating nitric oxide (NO) production [45], acting as a
scaffolding protein for the assembly of the vasoregulatory plasma kalli-
krein–kinin system [40]. The kallikrein–kinin system was ﬁrst recog-
nized as a plasma and tissue proteolytic system that is responsible for
the liberation of bradykinin, a vasoactive, proinﬂammatory mediator,
resulting in NO synthesis and liberation. Tissue plasminogen activator
release, superoxide formation, and prostacyclin formation are also in-
duced by bradykinin [45]. It is known that oxidative stress and circulat-
ing FABP4 levels are increased in metabolic diseases, such as T2DM and
obesity [19–25,50,51]. In our study, we hypothesized that oxidative
stress could be involved in FABP4-CK1 interaction. Previous results
from our group showed that exogenous FABP4 has a functional role in
endothelial cells, inducing endothelial dysfunction. Exogenous FABP4
inhibits the activation of the insulin-signaling pathway, resulting in de-
creased eNOS activation and NO production [33]. Therefore, the FABP4-
CK1 binding could decrease NO production and induce endothelial
dysfunction. We also demonstrated that FABP4 inhibition decreases
complex formation, likely by ameliorating endothelial dysfunction.
Furthermore, CK1 can be phosphorylated, suggesting that kininogen
bindingmay induce intracellular signaling [45]. Exogenous FABP4 is also
able to activate intracellular pathways (MAPK andAkt-dependent path-
ways) [33,34]; thus, it is possible that this activation also occurs through
the FABP4-CK1 interaction.
We showed that this interaction did not occur in HUVECs only but
that it also took place in other cell types, such as HAECs, HCASMCs,
HepG2 cells and THP-1 cells. These results suggest that high levels ofFABP4 in the circulation are not simply a clinical manifestation of car-
diometabolic risk but are also a causative factor for cardiovascular dis-
ease. It is especially striking that exogenous FABP4 was able to form a
protein complex with CK1 in HepG2 cells because these cells do not ex-
press FABP4, supporting the importance of the interaction of circulating
FABP4 with peripheral tissues.
In conclusion,we demonstrated that FABP4 is not just a biomarker of
metabolic diseases. Circulating FABP4 interacts with plasmamembrane
proteins, speciﬁcally CK1. Furthermore, FABP4 is able to cross the plas-
ma membrane into the cytoplasm and reach the nucleus, although its
role in this location is not fully known. Pharmacological inhibition of
FABP4 can modulate its mechanism of action, decreasing complex for-
mation and therefore reducing activity associated with the FABP4-CK1
interaction. Therefore, FABP4 represents a potential therapeutic target
for the prevention of cardiovascular diseases that are associated with
obesity and T2DM. Thus, the ﬁndings from this study and others suggest
that FABP4 inhibition should be explored as a potential therapeutic
strategy for treating atherosclerosis and reducing cardiovascular risk.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2015.09.002.
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